Minakem’s investment in a new production unit in Lassalle, Montreal, for corticosteroid APIs reflects the company’s recognition of the importance and growing demand for these active pharmaceutical ingredients (API). The limited number of manufacturing sites for steroid APIs in Northern America underscores the strategic significance of this investment.
This investment not only meets an unmet need in the region but also strengthens Minakem’s position in the global market, as this dedicated workshop complements Minakem’s existing steroid facility in Dunkirk, France, which produces budesonide.
By having production capabilities in both North America and Europe, Minakem enhances its ability to serve diverse markets and respond effectively to customer needs on multiple continents.
The COVID-19 pandemic highlighted the critical role of corticosteroids in treating severe cases of the disease. The 2020 findings of trials like RECOVERY have influenced treatment guidelines, emphasizing the efficacy of corticosteroids by advising preferably dexamethasone, alternatively methylprednisolone or prednisone in hospitalized patients with severe COVID-19. This therapeutical strategy has played a crucial role in reducing mortality and mitigating the impact of severe cases until vaccines have been widely administered to the population
Steroid therapy has demonstrated good performance in stabilizing patients’ condition, shortening duration of mechanical ventilation and thus reducing ICU stays. Over the decades, while their impact on mortality may not be entirely clear, their overall benefits in managing severe cases have been evident.
Minakem’s commitment to supporting customers in their development and reshoring projects aligns with the company’s confidence in the long-term prospects of steroid production. By offering their expertise and state-of-the-art capabilities, Minakem aims to contribute to the regional production of these vital pharmaceuticals. For inquiries or collaboration opportunities, interested parties can contact Minakem at api@minakem.com.
Stay in touch? Leave us your e-mail address to receive our latest news